logo-loader
viewTissue Regenix Group PLC

Tissue Regenix confirms US$300,000 grant for San Antonio facility

The regenerative medicine company said the funds would help upgrade utilities and infrastructure at the site

Tissue Regenix Group PLC - Tissue Regenix confirms US$300,000 grant for San Antonio facility

Tissue Regenix Group PLC (LON:TRX) has confirmed receipt of a US$300,000 grant to begin a build-out programme for a new 21,000 square foot facility in San Antonio, Texas.

The regenerative medicine company said the funds would help upgrade utilities and infrastructure at the site, while the technical staff needed to operate a second shift at its original facility in the city had been recruited and were in the process of being trained.

READ: Tissue Regenix develops product extension to be used in female pelvic medicine

Monthly processing throughput has already more than doubled in the year to the third quarter, TRX said, with additional products expected to become available towards the end of the fourth quarter.

The company added that it was currently working with its existing outsourcing provider to increase the yield of DermaPure, its soft tissue repair product.

"We have excellent products for which demand is exceeding our current capacity. Therefore, our current focus is ensuring we can increase our capacity to meet this significant demand", said TRX’s executive chairman John Samuel.

The group also released a trading update for its current full year, saying that an increase in throughput was now expected for the fourth quarter, as opposed to earlier in the second half, and as a result its revenues for 2019 were now expected to be 15-20% below current market consensus, which would, in turn, reduce its margins and impact earnings (EBITDA).

However, the firm reiterated that demand for its products “remains strong” and that it did not expect any longer-term impact beyond a current three-month delay to an increase of its manufacturing capacity.

In early trading on Thursday, Tissue Regenix shares were 9.5% lower at 2.9p.

Quick facts: Tissue Regenix Group PLC

Price: 1.2 GBX

AIM:TRX
Market: AIM
Market Cap: £14.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read